search
Back to results

tDCS to Prevent Relapse in Alcohol Use Disorder

Primary Purpose

Active tDCS, Sham tDCS

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
tDCS
Sponsored by
Brugmann University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Active tDCS focused on measuring tDCS, DLPFC, Alcohol use disorder, Relapse, Craving

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • French speaker
  • Severe Alcohol Use Disorder requiring alcohol rehabilitation
  • Desire to stay sober for at least the next six months

Exclusion Criteria:

  • Neurological history (epilepsy, head injury, and stroke)
  • Mental confusion or severe cognitive impairment
  • Schizophrenia, chronic psychotic disorders or bipolar type 1 disorder
  • Metal in the brain
  • Pregnancy
  • Having participated in our previous study combining tDCS with ICT

Sites / Locations

  • CHU-Brugmann

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Sham Comparator

Experimental

Experimental

Experimental

Arm Label

Early relapse (2-week follow-up)

Craving

Working memory

Depressive symptoms

Arm Description

We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.

We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.

We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.

We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.

Outcomes

Primary Outcome Measures

Relapse rate 2 weeks after discharge
by phone call; more than 60 g of alcohol
Relapse rate 1 month after discharge
by phone call; more than 60 g of alcohol
Relapse rate 3 months after discharge
by phone call; more than 60 g of alcohol

Secondary Outcome Measures

Craving
Visual Analog Scales (4 items, range 1-9 each; 1 = no craving, 9 = extreme craving)
Craving
Visual Analog Scales (4 items, range 1-9 each; 1 = no craving, 9 = extreme craving)
Working memory
Reverse memory span, range 2-9
Working memory
Reverse memory span, range 2-9
Depressive symptoms
Beck Depression Inventory II (BDI-II) [44], which assessed the severity of depressive symptoms (21 items; range, 0-63; 10-18 = mild depression, 19-29 = moderate depression, 30-63 = severe depression)
Depressive symptoms
Beck Depression Inventory II (BDI-II) [44], which assessed the severity of depressive symptoms (21 items; range, 0-63; 10-18 = mild depression, 19-29 = moderate depression, 30-63 = severe depression)
Anxiety state
The State-Trait Anxiety Inventory (STAI-Y) A which assessed the anxiety state (20 items; range, 20-80; < 35 = very low anxiety state, 36-45 = low anxiety state, 46-55 = medium anxiety state, 56-65 = high anxiety state, >65 = very high anxiety state).
Anxiety state
The State-Trait Anxiety Inventory (STAI-Y) A which assessed the anxiety state (20 items; range, 20-80; < 35 = very low anxiety state, 36-45 = low anxiety state, 46-55 = medium anxiety state, 56-65 = high anxiety state, >65 = very high anxiety state).

Full Information

First Posted
July 13, 2021
Last Updated
September 27, 2022
Sponsor
Brugmann University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04990375
Brief Title
tDCS to Prevent Relapse in Alcohol Use Disorder
Official Title
Placebo-controlled Randomized Clinical Trial: tDCS to Prevent Relapse in Alcohol Use Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
April 2, 2021 (Actual)
Primary Completion Date
June 6, 2022 (Actual)
Study Completion Date
June 6, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brugmann University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Despite the system of care in place, patients suffering from an alcohol use disorder (AUD) continue to relapse after their detoxification. For about twenty years, neuromodulations and their mechanisms have been investigated in research in order to apply it as a therapeutic means, in particular direct current transcranial stimulation (tDCS). A previous study found a reduction of relapse rate thanks to the tDCS over the dorsolateral prefrontal cortex (DLPFC; anode on the right and cathode on the left) combined with an ICT. This clinical trial of 5 sessions of tDCS alone on the DLPFC (20 minutes, anode on the right, cathode on the left). This study follows the same tDCS configuration as the previous one and takes place in the same multidisciplinary detoxification framework in order to see the relevance of using combined tDCS or only tDCS in clinical practice.
Detailed Description
Hypotheses: For patients with AUD five sessions of tDCS during a detoxification: decrease the relapse rate 2 weeks after the treatment; decrease patient craving; decrease depression and anxiety symptoms; strengthen working memory performances. Context: This is a clinical trial that is part of an alcohol detoxification cure at Unit 72 Addictology of CHU Brugmann. The idea is to add a neuromodulation intervention to the initial management, multidisciplinary and psycho-bio-social. This will be a randomized, sham-controlled, single-blind study. A total of 60 subjects will be recruited according to the inclusion and exclusion criteria. They will be randomly divided into two groups: the 'active' group (A) that will benefit from tDCS stimulation and the 'sham' group (S). Measures: Primary dependent variables : Relapse and total abstinence measured at several defined times: two weeks, one month, three months, six months and one year after treatment. Secondary dependent variables: Craving measured before and after each tDCS session via visual analog scales, such as Likert 0 to 10. Craving will also be measured in T1 and T2 through the Craving Experience Questionnaire (CEQ); Symptoms of depression with the Beck Depression Inventory (BDI-II) and positive and negative affectivity with the Positive and Negative Affect Schedule (PANAS) measured at T1 and T2; Anxiety trait in T1 and T2 with the State Anxiety Inventory (STAI-A). The working memory performance measured in T1 and T2 with the span reversed. All the questionnaires were in French version. Metacognition items: At the end of the experiment, patients will be asked orally (1) Do you think you are in the active tDCS group?, (2) Would you be interested in continuing this intervention over a longer period of time? Statistical analyses: Primary measurement: In order to respond to our primary assumptions about relapse, a logistic regressions will be performed with the independent variable conditions (tDCS active scored 1 and tDCS sham scored -1) and the variable dependent relapse at each measurement (2 weeks, 1 month, 3 months, 6 months and 1 year). A Kaplan-Meier survival analysis will be performed on the number of days prior to relapse to compare the curves up to one year of follow-up. Secondary measures: In order to respond to our secondary assumptions about the variables before and after the intervention, mixed repeated measures ANOVAs [Time (T1 vs. T2) x Condition (tDCS active vs. tDCS sham)] will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Active tDCS, Sham tDCS
Keywords
tDCS, DLPFC, Alcohol use disorder, Relapse, Craving

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
active tDCS vs. sham tDCS, while the patient is watching a documentary
Masking
Participant
Masking Description
sham tDCS protocol: 0 mA but 30s of 2 mA at the start and the end of the session
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early relapse (2-week follow-up)
Arm Type
Sham Comparator
Arm Description
We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
Arm Title
Craving
Arm Type
Experimental
Arm Description
We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
Arm Title
Working memory
Arm Type
Experimental
Arm Description
We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
Arm Title
Depressive symptoms
Arm Type
Experimental
Arm Description
We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
Intervention Type
Device
Intervention Name(s)
tDCS
Intervention Description
5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
Primary Outcome Measure Information:
Title
Relapse rate 2 weeks after discharge
Description
by phone call; more than 60 g of alcohol
Time Frame
2-week follow-up
Title
Relapse rate 1 month after discharge
Description
by phone call; more than 60 g of alcohol
Time Frame
1-month follow-up
Title
Relapse rate 3 months after discharge
Description
by phone call; more than 60 g of alcohol
Time Frame
3-month follow-up
Secondary Outcome Measure Information:
Title
Craving
Description
Visual Analog Scales (4 items, range 1-9 each; 1 = no craving, 9 = extreme craving)
Time Frame
at pre-intervention (day 12 of hospitalization)
Title
Craving
Description
Visual Analog Scales (4 items, range 1-9 each; 1 = no craving, 9 = extreme craving)
Time Frame
at post-intervention (day 22 of hospitalization)
Title
Working memory
Description
Reverse memory span, range 2-9
Time Frame
at pre-intervention (day 12 of hospitalization)
Title
Working memory
Description
Reverse memory span, range 2-9
Time Frame
at post-intervention (day 22 of hospitalization)
Title
Depressive symptoms
Description
Beck Depression Inventory II (BDI-II) [44], which assessed the severity of depressive symptoms (21 items; range, 0-63; 10-18 = mild depression, 19-29 = moderate depression, 30-63 = severe depression)
Time Frame
at pre-intervention (day 12 of hospitalization)
Title
Depressive symptoms
Description
Beck Depression Inventory II (BDI-II) [44], which assessed the severity of depressive symptoms (21 items; range, 0-63; 10-18 = mild depression, 19-29 = moderate depression, 30-63 = severe depression)
Time Frame
at post-intervention (day 22 of hospitalization)
Title
Anxiety state
Description
The State-Trait Anxiety Inventory (STAI-Y) A which assessed the anxiety state (20 items; range, 20-80; < 35 = very low anxiety state, 36-45 = low anxiety state, 46-55 = medium anxiety state, 56-65 = high anxiety state, >65 = very high anxiety state).
Time Frame
at pre-intervention (day 12 of hospitalization)
Title
Anxiety state
Description
The State-Trait Anxiety Inventory (STAI-Y) A which assessed the anxiety state (20 items; range, 20-80; < 35 = very low anxiety state, 36-45 = low anxiety state, 46-55 = medium anxiety state, 56-65 = high anxiety state, >65 = very high anxiety state).
Time Frame
at post-intervention (day 22 of hospitalization)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: French speaker Severe Alcohol Use Disorder requiring alcohol rehabilitation Desire to stay sober for at least the next six months Exclusion Criteria: Neurological history (epilepsy, head injury, and stroke) Mental confusion or severe cognitive impairment Schizophrenia, chronic psychotic disorders or bipolar type 1 disorder Metal in the brain Pregnancy Having participated in our previous study combining tDCS with ICT
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dubuson Macha, MA
Organizational Affiliation
Université Libre de Bruxelles
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU-Brugmann
City
Brussels
ZIP/Postal Code
1020
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

tDCS to Prevent Relapse in Alcohol Use Disorder

We'll reach out to this number within 24 hrs